Wang 2017c.

Methods	Study design: Randomised clinical trial Study duration: May 2012 to September 2014 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by pathology and images; single tumour, with tumour diameter ≤ 5 cm or multiple tumours (≤ 3) with tumour diameter ≤ 3 cm; AFP > 200 μg/L; with liver function of Child‐Pugh Class A or B; unwilling to receive liver resection Exclusion criteria: With the tumour near major vessels or organs; serious hypertension; tumour diameter ≥ 5 cm; with disseminated metastasis; abnormal haematopoietic function; with liver function of Child‐Pugh Class C Age (mean ± SD, range): TACE + RFA: 50.13 ± 8.75 years, 28‐65 years; TACE: 49.47 ± 9.13 years, 31‐66 years Male (n/total): TACE + RFA: 28/36; TACE alone: 26/36
Interventions	TACE + RFA group (n = 36): TACE: Chemotherapeutic drugs: 5‐fluorouracil 1‐1.5 g, oxaliplatin 50‐100 mg, and adriamycin 20‐40 mg RFA: The interval between TACE and RFA was 4 weeks. Ablation margin of 5‐10 mm TACE group (n = 36): Chemotherapeutic drugs: 5‐fluorouracil 1‐1.5 g, oxaliplatin 50‐100 mg, and adriamycin 20‐40 mg
Outcomes	Serum level of AFP 1‐ and 2‐year survival rates Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.